Tadalafil Patent Expiration
Tadalafil is used for improving exercise ability in patients with Pulmonary Arterial Hypertension (PAH). It was first introduced by Eli Lilly And Co
Tadalafil Patents
Given below is the list of patents protecting Tadalafil, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tadliq | US11382917 | Liquid oral formulations for tadalafil | Dec 24, 2038 | Cmp Dev Llc |
| Tadliq | US11666576 | Liquid oral formulations for tadalafil | Dec 24, 2038 | Cmp Dev Llc |
| Tadliq | US11975006 | Liquid oral formulations for tadalafil | Dec 24, 2038 | Cmp Dev Llc |
| Tadliq | US12186322 | Liquid oral formulations for tadalafil | Dec 24, 2038 | Cmp Dev Llc |
| Tadliq | US12691120 | Dec 24, 2038 | Cmp Dev Llc | |
| Tadliq | US12697338 | Dec 24, 2038 | Cmp Dev Llc | |
| Tadliq | US12708626 | Dec 24, 2038 | Cmp Dev Llc | |
| Tadliq | US12721849 | Dec 24, 2038 | Cmp Dev Llc | |
| Adcirca |
US6821975 (Pediatric) | Beta-carboline drug products |
May 19, 2021
(Expired) | Eli Lilly Co |
| Cialis |
US6821975 (Pediatric) | Beta-carboline drug products |
May 19, 2021
(Expired) | Lilly |
| Adcirca | US6821975 | Beta-carboline drug products |
Nov 19, 2020
(Expired) | Eli Lilly Co |
| Cialis | US6821975 | Beta-carboline drug products |
Nov 19, 2020
(Expired) | Lilly |
| Adcirca |
US7182958 (Pediatric) | β-carboline pharmaceutical compositions |
Oct 26, 2020
(Expired) | Eli Lilly Co |
| Cialis |
US6943166 (Pediatric) | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
Oct 26, 2020
(Expired) | Lilly |
| Cialis |
US7182958 (Pediatric) | β-carboline pharmaceutical compositions |
Oct 26, 2020
(Expired) | Lilly |
| Adcirca | US7182958 | β-carboline pharmaceutical compositions |
Apr 26, 2020
(Expired) | Eli Lilly Co |
| Cialis | US6943166 | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
Apr 26, 2020
(Expired) | Lilly |
| Cialis | US7182958 | β-carboline pharmaceutical compositions |
Apr 26, 2020
(Expired) | Lilly |
| Adcirca |
US5859006 (Pediatric) | Tetracyclic derivatives; process of preparation and use |
May 21, 2018
(Expired) | Eli Lilly Co |
| Cialis |
US5859006 (Pediatric) | Tetracyclic derivatives; process of preparation and use |
May 21, 2018
(Expired) | Lilly |
| Adcirca | US5859006 | Tetracyclic derivatives; process of preparation and use |
Nov 21, 2017
(Expired) | Eli Lilly Co |
| Cialis | US5859006 | Tetracyclic derivatives; process of preparation and use |
Nov 21, 2017
(Expired) | Lilly |
| Cialis | US6140329 | Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence |
Jul 11, 2016
(Expired) | Lilly |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Tadalafil's patents.
Latest Legal Activities on Tadalafil's Patents
Given below is the list recent legal activities going on the following patents of Tadalafil.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 31 Dec, 2025 | US11382917 |
| Patent Issue Date Used in PTA Calculation Critical
| 06 Jun, 2023 | US11666576 |
| Recordation of Patent eGrant | 06 Jun, 2023 | US11666576 |
| Recordation of Patent Grant Mailed Critical
| 06 Jun, 2023 | US11666576 |
| Electronic Review Critical
| 06 Jun, 2023 | US11666576 |
| Patent eGrant Notification | 06 Jun, 2023 | US11666576 |
| Email Notification Critical
| 06 Jun, 2023 | US11666576 |
| Mail Patent eGrant Notification | 06 Jun, 2023 | US11666576 |
| Electronic Review Critical
| 18 May, 2023 | US11666576 |
| Email Notification Critical
| 18 May, 2023 | US11666576 |
Tadalafil's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Tadalafil:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
